P2X3 receptor antagonists

A compound of Formula (I): Or an enantiomer, diastereomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein each A is independently C, N, S or O; X-Y represents in either orientation either N-C or N=C; groups R3 and R4, or alternatively R3 and R5 are linked to each other to from a five- or six-membered heterocyclic ring containing 2-3 heteroatoms selected from N, O and S, the ring optionally substituted with one or more R6 with the proviso that the remainder of R4 or R5 not linked with R3 is absent, or is independently selected from doubly-bonded N, O or S; wherein R1, R2 and R3 is as herein defined; and n is 0-3. R2 is preferably a hydrogen atom or an optionally substituted benzyl group or derivative thereof, in particular 2,5-dimethylbenzyl, 4-methoxybenzyl, 4-methylbenzykm 4-chlorobenzyl or 4-chloro-2,6-difluorobenzyl. The compounds are disclosed to be useful in pharmaceutical compositions, particularly in the treatment of P2X3 and P2X2/3 mediated diseases and disorders, ...

Flash EEPROM with integrated device for limiting the erase source voltage

A flash EEPROM having an array of memory cells which include a common source line connecting together source electrodes of the memory cells. A resistive feedback element is coupled in series between the common source line and a positive potential when the memory cells must be electrically erased. The Flash EEPROM includes a voltage limiting circuit coupled to the common source line for limiting the potential of the common source line to be prescribed maximum value lower than the positive potential.

Thienopyranecarboxamide derivatives

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists

Isoxazolecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N'-[omega-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

N,N-disubstituted diazocycloalkanes

N,N-Disubstituted diazocycloalkanes of the formula I (R¹=halogen, R²=(C₃-C₈)-cycloalkyl, R³=(C₁-C₄)-alkoxy or (C₁-C₄)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT_1A receptor.

Process for forming an edge structure to seal integrated electronic devices, and corresponding device

A process for the formation of a device edge morphological structure for protecting and sealing peripherally an electronic circuit integrated in a major surface of a substrate of semiconductor material. The electronic circuit is of the type that calls for formation above the major surface of at least one dielectric multilayer. The dielectric multilayer includes a layer of amorphous planarizing material having a continuous portion extending between two contiguous areas with a more internal first area and a more external second area in the morphological structure. The device edge morphological structure includes in the substrate an excavation on the side of the major surface at the more internal first area of the morphological structure in a zone in which is present the continuous portion of the dielectric multilayer.

Isoxazolecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N′-[(ω-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS

This invention relates to compounds of formula I, 114-. (canceled)16. The method according to claim 15 , wherein the disorder associated with glutamate dysfunction is selected from the group consisting of schizophrenia claim 15 , schizoaffective disorder claim 15 , substance induced psychotic disorder claim 15 , age-associated learning and memory impairments or losses claim 15 , post stroke dementia claim 15 , deficits in concentration claim 15 , mild cognitive impairment claim 15 , cognitive dysfunction in Alzheimers disease claim 15 , cognitive dysfunction of schizophrenia claim 15 , cognitive decline claim 15 , dementia claim 15 , cognitive impairment claim 15 , Fragile-X syndrome claim 15 , Rett syndrome claim 15 , Phelan-McDermid syndrome and tuberous sclerosis.17. The method according to claim 16 , wherein the disorder is selected from the group consisting of Fragile-X syndrome claim 16 , Rett syndrome claim 16 , Phelan-McDermid syndrome and tuberous sclerosis. This application claims priority to U.S. Provisional Patent Application Ser. No. 62/097,482, filed on Dec. 29, 2014, which is incorporated by reference in its entirety.This invention relates to heterocyclylalkynes and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction.Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in many physiological processes, such as synaptic plasticity, long term potentiation involved in both learning and memory as well as sensory perception ...

1-(N-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring

MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Phthalazine derivatives as phosphodiesterase 4 inhibitors

Compounds of formula I wherein R and R1 are as defined in the description. The compounds of formula I are PDE 4 inhibitors.

N,N-disubstituted diazocycloalkanes

N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.

NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Thienopyranecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N'-[omega-(5-substituted-7-oxo-7H-thieno[3,2-b]pyran-3-carbonylamino)alkyl]piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). The compounds are also useful in the treatment of excessive intraocular pressure, cardiac arrhythmia, erectile dysfunction, sexual dysfunction, and for inhibiting cholesterol synthesis or reducing sympathetically mediated pain.

N,N-disubstituted diazocycloalkanes

N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3-C8)-cycloalkyl, R3=(C1-C4)-alkoxy or (C1-C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.

NOVEL AMINO- AND IMINO-ALKYLPIPERAZINES

Described are novel amino- and iminoalkyl piperazines having affinity for serotonergic receptors and pharmacological compositions thereof. These compounds and their isomers, including optical isomers, enantiomers, diastereomers, N-oxides, polymorphs, hydrates, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and CNS diseases and/or disorders associated with 5-HT1A receptor dysfunction.

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Process for forming an integrated circuit comprising non-volatile memory cells and side transistors of at least two different types, and corresponding IC

A process for forming an integrated circuit calls for the provision of at least one matrix of non-volatile memory cells including an intermediate dielectric multilayer comprising a lower silicon oxide layer, an intermediate silicon nitride layer and an upper silicon oxide layer. The process calls for the simultaneous provision in zones peripheral to the memory cells of at least one first and one second transistor type each having a gate dielectric of a first and a second thickness respectively. After formation of the floating gate of the cells with a gate oxide layer and a polycrystalline silicon layer and the formation of the lower silicon oxide layer and of the intermediate silicon nitride layer, the process in accordance with the present invention includes removal of said layers from the zones peripheral to the matrix, and formation of a first silicon oxide layer over the substrate in the areas of both types of transistor. The process further includes removal of the preceding layer from ...

Novel N-acylated heterocycles

Described are novel N-acylated heterocycle derivatives having affinity for serotonergic receptors. These compounds and their enantiomers, diastercoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptor. Also described are the preparation of the compounds and the pharmaceutical compositions containing them

Thienopyrancecarboxamide derivatives

The invention is directed to compounds of Formula I:whereinR is an aryl, cycloalkyl or polyhaloalkyl group,R1 is chosen from the group consisting of alkyl, alkoxy, polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy; each of R2 and R3 independently is chosen from the group consisting of a hydrogen, halogen, alkoxy and polyfluoroalkoxy group, and n is 0, 1 or 2.The invention further provides pharmaceutical compositions comprising a compound of Formula I or a N-oxide or pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier.In another aspect, the present invention is directed to methods for selectively preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure, by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment in an amount or amounts effective for the particular use.In yet another aspect, the invention ...

HETEROCYCLIC M-GLU5 ANTAGONISTS

Compounds I 2. (canceled)3. (canceled)4. The compound of claim 1 , wherein Ris hydrogen or an optionally substituted mono- claim 1 , bi- or tricyclic C-Cheterocyclic group containing 1 to 5 heteroatoms selected from N claim 1 , O claim 1 , and S.5. The compound of claim 4 , wherein Ris an optionally substituted five membered heteroaromatic ring.6. The compound of claim 1 , wherein Ris an optionally substituted group selected from pyrazolyl claim 1 , benzofuranyl claim 1 , triazolyl claim 1 , benzothiazolyl claim 1 , tetrazolyl claim 1 , benzoxazolyl claim 1 , thiazolyl claim 1 , oxazolyl claim 1 , oxadiazolyl claim 1 , isoxazolyl claim 1 , benzimidalolyl claim 1 , benzothienyl claim 1 , thienobenzothienyl claim 1 , and indolyl claim 1 , and the optional substituent is selected from halogen claim 1 , alkyl claim 1 , alkoxy claim 1 , nitro claim 1 , amino claim 1 , hydroxyl claim 1 , carboxyl claim 1 , cyano claim 1 , and trifluoromethyl.7. (canceled)8. The compound of claim 1 , wherein Ris hydrogen or an optionally substituted monocyclic aromatic or C-Cheteroaromatic group containing from 1 to 4 heteroatoms selected from the group consisting of N claim 1 , S claim 1 , and O.9. The compound of claim 8 , wherein Ris optionally substituted phenyl.10. (canceled)11. The compound of claim 1 , wherein Ris an optionally substituted group selected from phenyl claim 1 , furanyl claim 1 , thienyl claim 1 , isoxazolyl claim 1 , and pyridinyl claim 1 , and the optional substituent is selected from halogen claim 1 , alkyl claim 1 , alkoxy claim 1 , nitro claim 1 , amino claim 1 , hydroxyl claim 1 , carboxyl claim 1 , cyano claim 1 , and trifluoromethyl.12. (canceled)13. The compound of claim 1 , wherein Ris an optionally substituted C-Calkyl group claim 1 , an optionally substituted mono- claim 1 , bi- or tricyclic C-Cheterocyclic group containing 1 to 5 heteroatoms selected from the group consisting of N claim 1 , S claim 1 , and O; an optionally substituted mono claim 1 , bi or ...

Isoxazolecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N'-[omega-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed. 4. The compound of claim 2 , wherein Ris nitrogen claim 2 , Ris absent claim 2 , and Ris an optionally substituted mono- or bicyclic or tricyclic C-Cheterocyclic group containing from 1 to 5 heteroatoms selected from N claim 2 , O claim 2 , and S.5. The compound of claim 4 , wherein Rrepresents an optionally substituted mono- claim 4 , bi- or tricyclic C-Cheterocyclic group containing 1 to 5 heteroatoms selected from N claim 4 , O claim 4 , and S. Even more preferably claim 4 , Ris an optionally substituted group selected from phenyl claim 4 , furanyl claim 4 , thienyl claim 4 , isoxazolyl claim 4 , pyridinyl claim 4 , and pyrazinyl.6. The compound of claim 5 , wherein the optional substituent on the Rgroup is selected from one or more of halogen claim 5 , alkyl claim 5 , alkoxy claim 5 , nitro claim 5 , amino claim 5 , hydroxyl claim 5 , carboxyl claim 5 , cyano claim 5 , and trifluoromethyl.7. The compound of claim 2 , wherein Ris carbon claim 2 , and Rand Rare linked together to form an optionally substituted methylene claim 2 , an optionally substituted oxime claim 2 , or a keto group.8. The compound of claim 7 , wherein Rand Rare linked together to form an methylene ...

HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS

This invention relates to compounds of formula I, 2. The compound according to claim 1 , wherein the optional substituents being independently selected from the group consisting of halogen atoms and C-Calkyl claim 1 , C-Calkoxy claim 1 , hydroxy claim 1 , mercapto claim 1 , nitro claim 1 , cyano claim 1 , oxo claim 1 , halo(C-C)alkyl claim 1 , halo(C-C)alkoxy claim 1 , C-Calkylthio claim 1 , C-Calkylsulphonyl claim 1 , C-Calkylcarbonyl claim 1 , sulphamoyl claim 1 , C-Calkylsulphamoyl claim 1 , di(C-C)alkyl sulphamoyl claim 1 , (C-C)alkoxycarbonyl and (C-C)alkylcarbonyl(C-C)alkyl groups claim 1 , and from groups of the formulae —NR*R* claim 1 , —C(═O)—NR*R* claim 1 , -A claim 1 , —O-A claim 1 , —C(═O)-A claim 1 , —(CH)q-A claim 1 , —NR**-A claim 1 , —C(═O)—NR**-A claim 1 , —NR**C(═O)-A and —O—C(═O)-A wherein each R* independently represents a hydrogen atom or a C-Calkyl claim 1 , C-Calkoxy claim 1 , C-Calkylcarbonyl claim 1 , phenyl or benzyl group claim 1 , R** represents a hydrogen atom or a C-Calkyl group claim 1 , q is an integer from 1 to 6 and A represents a phenyl group or a C-Cheterocyclic group containing from 1 to 3 heteroatoms selected from N claim 1 , O and S; a C-Ccycloalkyl group; each group A being optionally substituted with from 1 to 3 groups independently selected from halo claim 1 , hydroxy claim 1 , cyano claim 1 , nitro and C-Calkyl claim 1 , preferably wherein the optional substituents are independently selected from the groups consisting of halogen atoms and C-Calkyl groups.3. The compound according to claim 1 , wherein n=1.4. The compound according to claim 1 , wherein Ris a CO group.5. The compound according to claim 1 , wherein Ris an optionally substituted mono- or bicyclic C-Cheterocyclic group containing from 1 to 3 heteroatoms selected from nitrogen claim 1 , oxygen and sulfur claim 1 , or an optionally substituted group chosen from cycloalkyl claim 1 , alkoxy claim 1 , cycloalkyloxy claim 1 , aryloxy claim 1 , heteroaryloxy claim 1 , ...

Process for forming an integrated circuit comprising non-volatile memory cells and side transistors and corresponding IC

A process for forming an integrated circuit includes at least one matrix of non-volatile memory cells having an intermediate dielectric multilayer including at least a lower dielectric material layer and an upper silicon oxide layer. The integrated circuit includes at least one transistor simultaneously formed in zones peripheral to the matrix and having a gate dielectric of a first thickness. After formation of the floating gate with a gate oxide layer and a polycrystalline silicon layer and the formation of the lower dielectric material layer, the process includes removal of said layers from the peripheral zones of the matrix; deposition of said upper silicon oxide layer over the memory cells, and over the substrate in the areas of the peripheral transistors; and formation of a first silicon oxide layer at least in the areas of the peripheral transistors. A second transistor type can be formed having a gate dielectric of a second thickness, thinner than said first thickness, in successive ...

1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring

The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.

EEPROM memory cell with a single level of polysilicon programmable and erasable bit by bit

The cell is formed of a selection transistor, a detection transistor and a tunnel condenser. The detection Transistor has its own control gate formed with an n+ diffusion which is closed and isolated from those of the other cells of the same memory.

Thienopyranecarboxamide derivatives

The invention is directed to compounds of Formula I: wherein R is an aryl, cycloalkyl or polyhaloalkyl group, R1is chosen from the group consisting of alkyl, alkoxy, polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy; each of R2and R3independently is chosen from the group consisting of a hydrogen, halogen, alkoxy and polyfluoroalkoxy group, and n is 0, 1 or 2. The invention further provides pharmaceutical compositions comprising a compound of Formula I or a N-oxide or pharmaceutically acceptable salt of such a compound in admixture with a pharmaceutically acceptable diluent or carrier. In another aspect, the present invention is directed to methods for selectively preventing contractions of the urethra and lower urinary tract, without substantially affecting blood pressure, by administering one or more selected compounds of Formula I to a mammal (including a human) in need of such treatment in an amount or amounts effective for the particular use. In yet another aspect, the invention ...

NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Phenylalkylamines and pyridylalkylamines

Described are novel substituted phenylalkylamines and pyridylalkylamines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds lacking cladinose in position 3 having antiinflammatory activity and substantially free of antibiotic properties, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them as active ingredient.

Diarylalkylpiperazines active on the lower urinary tract

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are diarylalkylpiperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT_1A receptors, for treating disorders of the lower urinary tract.

1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring

The present invention is directed to novel 1-(N-phenylaminoalkyl)piperazine derivatives substituted at the position 2 of the phenyl ring. Pharmaceutical compositions comprising the compounds of the invention also are contemplated. The compounds of the present invention also are contemplated for use in treating neuromuscular dysfunction of the lower urinary tract in a mammal.

Manufacturing process for making single polysilicon level flash EEPROM cell

A flash EEPROM memory cell comprises source and drain regions defining a channel region therebetween, a floating gate and a control gate. The source and drain regions are first and second doped semiconductor regions of a first conductivity type formed in a first active area region of a semiconductor material layer of a second conductivity type; the control gate comprises a third doped semiconductor region of the first conductivity type formed in a second active area region of the semiconductor material layer; and the floating gate comprises a polysilicon strip insulatively disposed over the channel region and insulatively extending over the third doped semiconductor region.

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Novel aldosterone antagonists and uses thereof

The present invention relates to novel compounds that are aldosterone receptor antagonists, to pharmaceutical compositions containing the aldosterone receptor antagonists, and to methods of treatment using the same.

Thienopyranecarboxamide derivatives

The invention relates to novel N-(substituted phenyl)-N'-[omega-(5-substituted-7-oxo-7H-thieno[3,2-b]pyran-3-carbonylamino)alkyl]piperazines their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neutogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.

Novel N-acylated heterocycles

Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1Areceptors.

1,4-disubstituted piperazines

Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are 1,4-disubstituted piperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT 1A receptors, for treating disorders of the lower urinary tract.

Heterocyclic derivatives as M-GLU5 antagonists

This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).

Spiroheterocyclic compounds as mGlu5 antagonists

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Benzopyran derivatives

The invention relates to novel benzopyran derivatives of formula I, their N-oxides and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS), neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.

1-Phenylalkylpiperazines

Described are novel 1-phenylalkylpiperazines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor activity. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.

HARDWARE AND TOKEN BASED USER AUTHENTICATION

Systems and methods for data visualization are disclosed. An example method includes: obtaining, via a user device, first user biometric data from a user; comparing the first user biometric data with first stored user biometric data. The first stored user biometric data are stored in a hardware secure element of the user device. The method further includes: determining that the first user biometric data matches the first stored user biometric data; and in response to the determining, transmitting a payment token to a merchant device. The payment token is configured to enable a payment to be made from a payment account associated with the user to a merchant associated with the merchant device. 1. A method , comprising:obtaining, via a user device, first user biometric data from a user;comparing the first user biometric data with first stored user biometric data, wherein the first stored user biometric data is stored in a hardware secure element of the user device;determining that the first user biometric data matches the first stored user biometric data; andin response to the determining, transmitting a payment token to a merchant device, wherein the payment token is configured to enable a payment to be made from a payment account associated with the user to a merchant associated with the merchant device.2. The method of claim 1 , further comprising: determining one or more restrictions on transmitting the payment token to the merchant device.3. The method of claim 2 , wherein the one or more restrictions include one of: a location restriction claim 2 , a time restriction claim 2 , and an amount restriction.4. The method of claim 2 , further comprising:determining that at least one restriction is triggered; andin response to the determining, disabling the payment token.5. The method of claim 1 , wherein the payment token is wirelessly transferred to the merchant device.6. The method of claim 1 , wherein the first user biometric data includes one of: a voice ...

SYSTEM CONFIGURATIONS BASED ON TILT DETECTION

Various systems, mediums, and methods herein describe a computing system that includes a tilt sensor and a transceiver. The system is configured to determine one or more tilts of the system detected by the tilt sensor. The system is also configured to determine a scan interval and a rest interval based on the one or more tilts detected. The system is also configured to provide scanning power to cause a transceiver of the system to scan an environment for one or more signals of interest based on the scan interval and the rest interval. As such, the one or more signals may be identified from the scan of the environment. 1a non-transitory memory; and determining one or more tilts of the mobile computing system detected by a tilt sensor;', 'determining a scan interval and a rest interval based at least on the one or more tilts of the mobile computing system detected;', 'providing scanning power to cause a transceiver of the mobile computing system to scan an environment for one or more signals of interest based at least on the scan interval and the rest interval; and', 'identifying the one or more signals of interest from the scan of the environment., 'one or more processors coupled to the non-transitory memory and configured to read instructions from the non-transitory memory to cause the mobile computing system to perform operations comprising. A mobile computing system, comprising: This continuation patent application claims priority to and the benefit of U.S. patent application Ser. No. 15/174,536, filed Jun. 6, 2016, and issued on Jun. 26, 2018 as U.S. Pat. No. 10,009,847 which claims priority to U.S. Provisional Patent App. No. 62/257,209 entitled “Power Management Based on Tilt Detection,” filed on Nov. 18, 2015, the entireties of which is herein incorporated by reference.Computing devices are becoming increasingly more prevalent in the modern world. In particular, it is not uncommon for a single user to own more than one mobile device or possibly utilize ...

WEARABLE PAYMENT DEVICE

A wearable device receives authentication information from a user. In response to verifying the authentication information, the wearable device provides the user with access to one or more payment capabilities of the wearable device. In response to determining that the wearable device has been switched into an open state, the wearable device removes access to the one or more payment capabilities of the wearable device. 1. (canceled)2. A wearable device , comprising:one or more computer-readable memories storing program instructions; and in response to determining that a first portion of a wearable device is electrically or magnetically connected to a second portion of the wearable device, enabling authentication information to be received from a user;', 'in response to receiving the authentication information from the user, utilizing the authentication information to authenticate the user;', 'in response to authenticating the user, enabling a payment functionality of the wearable device to be utilized by the user; and', 'in response to enabling the payment functionality, transmitting, during a first time period, a first payment based on the wearable device being within a first proximity of a first device., 'one or more processors configured to execute the program instructions to cause the system to perform operations comprising3. The wearable device of claim 2 , wherein the first payment is transmitted without requiring input of the authentication information by the user.4. The wearable device of claim 2 , the operations further comprising:transmitting, during a second time period, a second payment based on the wearable device being within the first proximity of the first device or a second device, wherein the second payment is transmitted without requiring input of the authentication information by the user.5. The wearable device of claim 2 , wherein the authentication information includes fingerprint information claim 2 , voice information claim 2 , retinal ...

TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS

Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR 5 .

DEVICE FOR FACILITATION OF PAYMENTS

A payment device comprising of a housing, a slot for insertion of a user instrument located on a front surface of the housing, and wherein the housing includes a smart card interface integrated circuit that is configured to read an EMV chip located on the user instrument, and a universal serial bus (USB) type C male connector configured to be inserted into a female connector on a computing device, wherein the USB type C male connector is located on a back surface of the housing, and wherein a size of the USB type C male connector is configured so that when the USB type C male connector is inserted into the female connector on the computing device, the back surface of the housing is within a distance of three centimeters of a surface of the computing device. 18-. (canceled)9. A payment device , comprising:a housing;a slot for insertion of a user instrument located on a front surface of the housing, and wherein the housing includes a smart card interface integrated circuit (IC) that is configured to read an EMV chip located on the user instrument; anda universal serial bus (USB) type C or micro-USB male connector configured to be inserted into a female connector on a computing device, wherein the USB type C or micro-USB male connector is located on a back surface of the housing, and wherein a size of the USB type C or micro-USB male connector is configured so that when the USB type C or micro-USB male connector is inserted into the female connector on the computing device, the back surface of the housing is within a distance of two centimeters of a surface of the computing device.10. The payment device of claim 9 , wherein the slot for insertion of the user instrument has a height of less than one millimeter.11. The payment device of claim 9 , further comprising a fingerprint reader located on a top surface of the payment device.12. The payment device of claim 11 , further comprising two or more fingerprint readers located on a bottom surface of the payment device.13. ...

SECURE OFFLINE TRANSACTION SYSTEM USING DIGITAL TOKENS AND A SECURE LEDGER DATABASE

A payer transaction device enables secure offline transactions using a secure element providing a secure payer account database, a secure ledger database, and a wallet application. While the payer transaction device is not connected to the Internet, the wallet application receives a payee identifier and a transaction amount and verifies that the transaction amount is less than an available payer account balance in the secure payer account database. In response, the wallet application creates a digital token that allocates the transaction amount from the payer account balance to the payee identifier, and records the digital token in a payer secure ledger in the secure ledger database, which reduces the available payer account balance by the transaction amount. The wallet application then transfers the digital token to a payee transaction device over a peer-to-peer wireless connection and, subsequently, the digital token is synchronized with a ledger tracking system through the Internet. 1. (canceled)2. A payer device , comprising:a wireless communication subsystem; anda secure element subsystem that is coupled to the wireless communication subsystem, wherein the secure element subsystem includes:an available payer account balance;a payer secure ledger; and establish, for a transaction being initiated between the payer device and a payee device and responsive to the payer device not able to connect to the Internet to complete the transaction, a first peer-to-peer wireless connection between the payer device and the payee device;', 'transfer, by the wallet application and over the first peer-to-peer wireless connection while the payer device is not connected to the Internet, a digital token to the payee device, the digital token indicating allocation of a first transaction amount from the available payer account balance to a first payee identifier;', 'establish an ad-hoc network with at least one local device using at least one peer-to-peer wireless connection;', ' ...

DYNAMICALLY ADJUSTING VISUAL CODES DISPLAYED ON A DEVICE

A system is configured to perform operations that include causing a merchant device to display a first visual code. The operations further include receiving a request to initiate a payment transaction between a consumer and a merchant, the request to initiate the payment transaction being transmitted to the system in response to a consumer device of the consumer scanning the first visual code displayed by the merchant device. The operations also include causing funds to be transferred from an account of the consumer to an account of the merchant. Further, the operations include in response to determining, based on one or more criteria, an occurrence of a code change event, causing the merchant device to display a second visual code in replacement of the first visual code. 1. A system , comprising:one or more hardware processors; and receiving a request to connect with a merchant device of a merchant, the request including a device identifier corresponding to the merchant device;', 'subsequent to establishing an electronic connection with the merchant device based on the request, causing the merchant device to display a first visual code based on the device identifier included in the request;', 'receiving a request to initiate a payment transaction between a consumer and the merchant, the request to initiate the payment transaction being transmitted to the system in response to a consumer device of the consumer scanning the first visual code displayed by the merchant device;', 'causing the consumer device to generate a user interface displaying a request for a payment amount to entered;', 'subsequent to receiving an entered payment amount corresponding to the displayed request on the user interface, causing funds equal to the entered payment amount to be transferred from an account of the consumer to an account of the merchant; and', 'in response to determining, based on one or more criteria, an occurrence of a code change event, causing the merchant device to ...

SECURE OFFLINE TRANSACTION SYSTEM USING DIGITAL TOKENS AND A SECURE LEDGER DATABASE

A payer transaction device enables secure offline transactions using a secure element providing a secure payer account database, a secure ledger database, and a wallet application. While the payer transaction device is not connected to the Internet, the wallet application receives a payee identifier and a transaction amount and verifies that the transaction amount is less than an available payer account balance in the secure payer account database. In response, the wallet application creates a digital token that allocates the transaction amount from the payer account balance to the payee identifier, and records the digital token in a payer secure ledger in the secure ledger database, which reduces the available payer account balance by the transaction amount. The wallet application then transfers the digital token to a payee transaction device over a peer-to-peer wireless connection and, subsequently, the digital token is synchronized with a ledger tracking system through the Internet. 1. A secure offline transaction system , comprising:a chassis;a wireless communication subsystem located in the chassis; and a secure payer account database that stores an available payer account balance;', 'a secure ledger database that stores a payer secure ledger; and', receive a first payee identifier and a first transaction amount;', 'verify that the first transaction amount is less than the available payer account balance stored in the secure payer account database;', 'create, in response to verifying that the first transaction amount is less than the available payer account balance, a digital token that allocates the first transaction amount from the available payer account balance to the first payee identifier;', 'record the digital token in the payer secure ledger as part of a first transaction, wherein the recording of the digital token in the payer secure ledger reduces the available payer account balance by the first transaction amount; and', 'transfer, over a peer-to-peer ...

REHEARSAL-BASED PRESENTATION ASSISTANCE

Examples are disclosed that relate to providing transition-related assistance during a presentation. One example provides a method comprising, during a rehearsal of a presentation, receiving content of the presentation. Based on the content received, a transition within the presentation is determined via a machine learning model. During a performance of the presentation, the transition is automatically enacted. 1. At a computing system , a method of providing transition-related assistance during a presentation , the method comprising: receiving content of the presentation, and', 'based on the content received, determining via a machine learning model a transition within the presentation; and, 'during a rehearsal of the presentation,'}during a performance of the presentation, automatically enacting the transition.2. The method of claim 1 , wherein receiving the content of the presentation comprises receiving from a user during the rehearsal a user input specifying the transition claim 1 , and wherein determining the transition via the machine learning model comprises associating the user input with a user performance of a portion of the presentation.3. The method of claim 2 , wherein the portion of the presentation comprises a spoken phrase.4. The method of claim 2 , wherein the user performance of the portion of the presentation comprises a user performance of a gesture and/or a movement to a different location.5. The method of claim 1 , wherein determining via the machine learning model the transition comprises claim 1 , during the rehearsal of the presentation:automatically detecting one or more possible transitions within the presentation; andpresenting, to the user, the one or more possible transitions.6. The method of claim 5 , further comprising one of:receiving an input selecting one of the one or more possible transitions; andreceiving an input specifying an alternate transition that is different from the one or more possible transitions.7. The method of ...

SYSTEM CONFIGURATIONS BASED ON TILT DETECTION

Various systems, mediums, and methods herein describe a computing system that includes a tilt sensor and a transceiver. The system is configured to determine one or more tilts of the system detected by the tilt sensor. The system is also configured to determine a scan interval and a rest interval based on the one or more tilts detected. The system is also configured to provide scanning power to cause a transceiver of the system to scan an environment for one or more signals of interest based on the scan interval and the rest interval. As such, the one or more signals may be identified from the scan of the environment. 1. A mobile computing system , comprising:a non-transitory memory; and determining one or more tilts of the mobile computing system detected by a tilt sensor;', 'determining a scan interval and a rest interval based at least on the one or more tilts of the mobile computing system detected;', 'providing scanning power to cause a transceiver of the mobile computing system to scan an environment for one or more signals of interest based at least on the scan interval and the rest interval; and', 'identifying the one or more signals of interest from the scan of the environment., 'one or more processors coupled to the non-transitory memory and configured to read instructions from the non-transitory memory to cause the mobile computing system to perform operations comprising2. The mobile computing system of claim 1 , wherein the operations further comprise terminating the scanning power based at least on the one or more signals identified.3. The mobile computing system of claim 1 , wherein the operations further comprise:providing the scanning power to cause the transceiver to further scan the environment for one or more additional signals of interest based at least on the one or more signals identified; andterminating the scanning power based at least on scanning for the one or more additional signals of interest.4. The mobile computing system of claim 1 , ...

Electronic Transaction Fobs

Systems and methods for electronic fobs that communicate via short range communications protocols to conduct transactions with a nearby device are provided. Such electronic fobs may use electronic tokens to conduct electronic transactions, such as payment transactions. Account data may be stored within a secure element of the electronic fob. Electronic tokens may also be stored by the secure element. Using such data and/or tokens, electronic fob may write electronic tokens to be used in electronic transactions. Also, such electronic fobs may also be used to perform other tasks and interface with other devices. 1. A fob comprising:a body comprising a front surface and a top surface;an input button disposed on the front surface of the body;a plurality of scrolling buttons disposed on the front surface of the body;a display disposed on the front surface of the body;an authentication sensor disposed on the top surface of the body;a secure element configured to store account data;a non-transitory memory; and receiving, via the input button, an indication to conduct an electronic transaction with a merchant device using a user account associated with a service provider;', 'in response to the receiving, determining, via the secure element, an electronic token comprising transaction data based on the electronic transaction and the user account; and', 'communicating, through a short range communications protocol, the electronic token to the merchant device independent of any communications to the service provider., 'one or more hardware processors coupled to the non-transitory memory and configured to read instructions from the non-transitory memory to cause the fob to perform operations comprising2. The fob of claim 1 , wherein the operations further comprise:communicatively coupling, through an intermediate range communications protocol, to a secondary device; andactivating, after communicatively coupling to the secondary device, the fob for use with the user account.3. ...

MODULAR MOBILE POINT OF SALE DEVICE HAVING SEPARABLE UNITS FOR CONFIGURABLE DATA PROCESSING

There are provided systems and methods for a modular mobile point of sale device having separable units for configurable data processing. A modular device may include a main unit that includes data processing features to allow for a mobile point of sale, including a data entry unit for payment data, a communication component to secure communicate that data to a centralized transaction processor, and a processing unit to receive the data and instruct the centralized to process the data with an online service provider. The module device may also be physically and communicatively coupled to additional modules that may increase the on-device functionality of the main unit, include a module to allow user input and additional modules to accept other types of transaction input. On detection of a connected unit, the main unit may secure connect to and authenticate each attached module. 1. A modular point of sale system comprising: a power source;', 'a first communication component configured to connect with a first computing device;', 'a payment card chip reader;', 'a non-transitory memory storing instructions; and', connecting with the first computing device using the first communication component;', 'determining a first available data input component for the first hardware module, wherein the first available data input component comprises the payment card chip reader;', 'determining a data input and processing operation for the modular point of sale system based on the first computing device and the first available data input component; and', 'configuring the modular point of sale system for electronic transaction processing with an online service provider based on the data input and processing operation., 'one or more hardware processors couple to the non-transitory memory and configured to read the instructions from the non-transitory memory to cause the first hardware module to perform operations comprising], 'a first hardware module comprising2. The modular point of ...

P2X3 RECEPTOR ANTAGONISTS

This invention relates to compounds of formula I; 2. A compound according to wherein the optional substituents are independently selected from the group consisting of halogen atoms claim 1 , C-Calkyl claim 1 , C-Calkoxy claim 1 , hydroxy claim 1 , mercapto claim 1 , nitro claim 1 , cyano claim 1 , oxo claim 1 , halo(C-C)alkyl claim 1 , halo(C-C)alkoxy claim 1 , C-Calkylthio claim 1 , C-Calkylsulphonyl claim 1 , C-Calkylcarbonyl claim 1 , sulphamoyl claim 1 , C-Calkylsulphamoyl claim 1 , di(C-C)alkylsulphamoyl claim 1 , (C-C)alkoxycarbonyl and (C-C)alkylcarbonyl(C-C)alkyl groups claim 1 , and from groups of the formulae —NR*R* claim 1 , —C(═O)—NR*R* claim 1 , -D claim 1 , —O-D claim 1 , —C(═O)-D claim 1 , —(CH)q-D claim 1 , —NR**-D claim 1 , —C(═O)—NR**-D claim 1 , —NR**C(═O)-D and —O—C(═O)-D wherein each R* independently represents a hydrogen atom or a C-Calkyl claim 1 , C-Calkoxy claim 1 , C-Calkylcarbonyl claim 1 , phenyl or benzyl group claim 1 , R** represents a hydrogen atom or a C-Calkyl group claim 1 , q is an integer from 1 to 6 and D represents a phenyl group or a C-Cheterocyclic group containing from 1 to 3 heteroatoms selected from N claim 1 , O and S; a C-Ccycloalkyl group; each group D being further optionally substituted with from 1 to 3 groups independently selected from halo claim 1 , hydroxy claim 1 , cyano claim 1 , nitro and C-Calkyl claim 1 , preferably wherein the optional substituents are selected from the groups consisting of halogen atoms and C-Calkyl groups.3. A compound according to or claim 1 , wherein group X—Y represents a N—C group claim 1 , groups Rand Rare linked to each other to form a five- or six-membered heterocyclic ring containing from 2 to 3 nitrogen heteroatoms atoms claim 1 , optionally substituted with one or more groups nR claim 1 , and Ris a carbonyl group.4. A compound according to or claim 1 , wherein group X—Y represents a N—C group claim 1 , groups Rand Rare linked to each other to form a five-membered heterocyclic ...

MODULAR MOBILE POINT OF SALE DEVICE HAVING SEPARABLE UNITS FOR CONFIGURABLE DATA PROCESSING

There are provided systems and methods for a modular mobile point of sale device having separable units for configurable data processing. A modular device may include a main unit that includes data processing features to allow for a mobile point of sale, including a data entry unit for payment data, a communication component to secure communicate that data to a centralized transaction processor, and a processing unit to receive the data and instruct the centralized to process the data with an online service provider. The module device may also be physically and communicatively coupled to additional modules that may increase the on-device functionality of the main unit, include a module to allow user input and additional modules to accept other types of transaction input. On detection of a connected unit, the main unit may secure connect to and authenticate each attached module. 1. (canceled)2. A method comprising:accessing, by a first device, a first data input component available to the first device, wherein the first data input component is external to the first device;enabling a transaction processing operation of the first device to receive transaction data based on accessing the first data input component;receiving, by the first device, the transaction data from the first data input component using the transaction processing operation; andprocessing, by the first device, the transaction data with an online service provider based on the transaction processing operation.3. The method of claim 2 , wherein said accessing the first data input component comprises the first device determining that the first data input is communicatively coupled to the first data input component.4. The method of claim 3 , wherein said accessing the first data input component comprises authenticating the first data input component using a security handshake between the first device and the first data input component on a connection of the first data input component to the first device.5 ...

PHYSICAL STAND FOR MULTIPLE DEVICE ORIENTATIONS AND PERIPHERAL CARD READER

There are provided systems and methods for a physical stand for multiple device orientations and peripheral card reader. A device stand may include a dock that allows for placement and securing of a computing device within the device case, such as through a locking or connecting mechanism. The device dock further includes a peripheral component, such as a physical card reader, that allows for reading and entry of card data into the computing device for use with an electronic transaction processing application on the computing device. This allows the computing device to process transactions electronic with an online service provider. Further, the device stand includes a hinge or joint that allows for rotating and inverting of the computing device over a curved extension from a base of the device stand, which allows the computing device to be viewed in multiple directions and orientations. 1. A device stand comprising:a base comprising an extension in a direction perpendicular from the base;a device docking case connected to the base via the extension, the device docking case configured to accept a mobile computing device, and the device docking case comprising an opening for insertion of a payment card or an opening for a protrusion of a portion of a payment card reader component from the device docking case;a rotatable joint connecting the extension and the device docking case, the rotatable joint configured to enable the device docking case to rotate over the extension; and detecting a physical connection of the payment card reader component to the mobile computing device, wherein the physical connection causes power to be provided to the payment card reader component from the mobile computing device;', 'connecting to the mobile computing device for data communications via the physical connection; and', 'activating the payment card reader component for reading the payment card., 'the payment card reader component at least partially within the device docking case, ...

Hardware and token based user authentication

Systems and methods for data visualization are disclosed. An example method includes: obtaining, via a user device, first user biometric data from a user; comparing the first user biometric data with first stored user biometric data. The first stored user biometric data are stored in a hardware secure element of the user device. The method further includes: determining that the first user biometric data matches the first stored user biometric data; and in response to the determining, transmitting a payment token to a merchant device. The payment token is configured to enable a payment to be made from a payment account associated with the user to a merchant associated with the merchant device.

SMART HARBOR DEVICE FOR INTELLIGENT UPDATING AND SELECTION FOR USE OF TRANSACTION PROCESSING TERMINAL DEVICES

There are provided systems and methods for a smart harbor device for intelligent updating and selection for use of transaction processing terminal devices. A smart harbor device may be used to provide updating, servicing, and other maintenance of transaction processing terminal devices, such as EMV terminals used in retail transaction processing. The smart harbor device may include a port where the transaction processing terminal devices may be places, and the smart harbor device may connect to each of the transaction processing terminal devices. Once connected, the smart harbor device may run diagnostics to determine the statuses and conditions for each of the transaction processing terminal devices and maintenance the transaction processing terminal devices. The maintenance may be performed at times where the transaction processing terminal devices are not required for use. Additionally, the smart harbor device may intelligently select one based on statuses and device capabilities. 1. A terminal harbor device comprising:a port structure configured to accept at least one transaction processing terminal device for management of resources of the at least one transaction processing terminal device;a power source;at least one power connector configured to provide power to charge the at least one transaction processing terminal device;a communication component configured to connect to a plurality of devices, wherein the plurality of devices comprise the at least one transaction processing terminal device and at least one communication device of a user;a non-transitory memory storing a terminal processing application; and receiving device data for the at least one transaction processing terminal device from the communication component, wherein the communication component connects to the at least one transaction processing terminal device;', 'determining a condition of the at least one transaction processing terminal device;', 'determining that the condition requires ...

HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS

This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction. 2. A compound according to wherein the optional substituents are independently selected from the group consisting of halogen atoms claim 1 , C-Calkyl claim 1 , C-Calkoxy claim 1 , hydroxy claim 1 , mercapto claim 1 , nitro claim 1 , cyano claim 1 , oxo claim 1 , halo(C-C)alkyl claim 1 , halo(C-C)alkoxy claim 1 , C-Calkylthio claim 1 , C-Calkylsulphonyl claim 1 , C-Calkylcarbonyl claim 1 , sulphamoyl claim 1 , C-Calkylsulphamoyl claim 1 , di(C-C)alkylsulphamoyl claim 1 , (C-C)alkoxycarbonyl and (C-C)alkylcarbonyl(C-C)alkyl groups claim 1 , and from groups of the formulae —NR*R* claim 1 , —C(═O)—NR*R* claim 1 , -D claim 1 , —O-D claim 1 , —C(═O)-D claim 1 , —(CH)q-D claim 1 , —NR**-D claim 1 , —C(═O)—NR**-D claim 1 , —NR**C(═O)-D and —O—C(═O)-D wherein each R* independently represents a hydrogen atom or a C-Calkyl claim 1 , C-Calkoxy claim 1 , C-Calkylcarbonyl claim 1 , phenyl or benzyl group claim 1 , R** represents a hydrogen atom or a C-Calkyl group claim 1 , q is an integer from 1 to 6 and D represents a phenyl group or a C-Cheterocyclic group containing from 1 to 3 heteroatoms selected from N claim 1 , O and S; a C-Ccycloalkyl group; each group D being further optionally substituted with from 1 to 3 groups independently selected from halo claim 1 , hydroxy claim 1 , cyano claim 1 , nitro and C-Calkyl claim 1 , preferably wherein the optional substituents are selected from the groups consisting of halogen atoms and C-Calkyl groups.5. A compound according to claim 1 , wherein Ris ...

WEARABLE PAYMENT DEVICE

A wearable device receives authentication information from a user. In response to verifying the authentication information, the wearable device provides the user with access to one or more payment capabilities of the wearable device. In response to determining that the wearable device has been switched into an open state, the wearable device removes access to the one or more payment capabilities of the wearable device. 1. A wearable device , comprising:one or more computer-readable memories storing program instructions; and receiving authentication information from a user;', 'in response to verifying the authentication information, providing the user with access to one or more payment capabilities of the wearable device; and', 'in response to determining that the wearable device has been switched into an open state, removing access to the one or more payment capabilities of the wearable device., 'one or more processors configured to execute the program instructions to cause the system to perform operations comprising2. The wearable device of claim 1 , wherein the authentication information includes fingerprint information claim 1 , voice information claim 1 , retinal information claim 1 , or facial image information.3. The wearable device of claim 1 , wherein the providing the user with access to one or more payment capabilities of the wearable device includes activating a secure element that contains a payment application.4. The wearable device of claim 1 , wherein the providing the user with access to one or more payment capabilities of the wearable device is based on detecting that the wearable device is in a closed state.5. The wearable device of claim 4 , wherein the detecting that the wearable device is in the closed state includes detecting that an electrical or magnetic connection between a first and a second portion of the wearable device has been made.6. The wearable device of claim 1 , wherein the detecting that the wearable device has been switched to ...

SMART HARBOR DEVICE FOR INTELLIGENT UPDATING AND SELECTION FOR USE OF TRANSACTION PROCESSING TERMINAL DEVICES

There are provided systems and methods for a smart harbor device for intelligent updating and selection for use of transaction processing terminal devices. A smart harbor device may be used to provide updating, servicing, and other maintenance of transaction processing terminal devices, such as EMV terminals used in retail transaction processing. The smart harbor device may include a port where the transaction processing terminal devices may be places, and the smart harbor device may connect to each of the transaction processing terminal devices. Once connected, the smart harbor device may run diagnostics to determine the statuses and conditions for each of the transaction processing terminal devices and maintenance the transaction processing terminal devices. The maintenance may be performed at times where the transaction processing terminal devices are not required for use. Additionally, the smart harbor device may intelligently select one based on statuses and device capabilities. 1. (canceled)2. A system comprising:a plurality of mobile payment terminals including a first mobile payment terminal;a non-transitory memory; and detecting a first connection to the first mobile payment terminal;', 'in response to the detecting, receiving a software status for the first mobile payment terminal;', 'determining that the software status requires a software update prior to a use of the first mobile payment terminal for transaction processing;', 'determining the software update for the software status;', 'performing the software update of the first mobile payment terminal;', 'updating a status of the first mobile payment terminal to a ready to use mode; and', 'in response to the updating, connecting the first mobile payment terminal to a communication device within a pairing range of the system., 'one or more hardware processors coupled to the non-transitory memory and configured to read instructions from the non-transitory memory to cause the system to perform operations ...

NEW OSSIALCHILPIPERAZINE

Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities

This invention provides bicyclic heterocyclic derivatives and their pharmaceutically acceptable salts useful for the treatment of hypertension, urethral and lower urinary tract contractions, and other disorders. The compounds are also useful for binding alpha 1-adrenergic and 5HT1A serotonergic receptors, in vitro or in vivo.

PROCESS FOR PROCESSING A PREFORM FOR THE PRODUCTION OF A CONTAINER BY BLOWING

The invention concerns a method for treating a preform made of an injected thermofusible polymer for producing a container by blow moulding, which consists in applying to the preform a thermal radiation and ultrasonic vibrations, in particular for reducing said preform pre-heating time and improving its physical characteristics. Said ultrasonic vibrations are applied to the preform by directly contacting it with a sonotrode or indirectly using an intermediate liquid which is both in contact with the sonotrode associated with an ultrasound generator and the preform. One process consists in using a sonotrode adapted to the preform neck and mounting said preform by its neck directly on the sonotrode.

PROCEDURE FOR THE PREPARATION OF ENANTIOMERALLY PURE POLICY SUBSTITUTED 1,4-DIHYDROPYRIDINES.

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Heterocyclic compounds for use in the treatment of disorders of the urinary tract

Compounds of formula (I) are thus useful for treating disorders of the urinary tract. In the compounds I, R1 = one or more substituents selected from H, halogen, OH, alky], haloalkyl, alkoxy, haloalkoxy, NO2, nitro, phenyl, substituted phenyl, heterocycle, substituted heterocycle, NR3R4(R3 andR4 being H, alkyl; Y + CH2 or a bond; Q = CO, CS or SO2; A= alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, alkylamino, arylamino or alkylamino, each of which is optionally substituted; n is ! or @; X= an amino molety selected(a), (b and -N(R5)-CH2-(R5 = H, methyl, benzyl group; W = bond, N, CH, CH2, C(CN) C(OH) or C(COCH3) (when W represents a nitrogen atom or a CH C(CN) C(OH) or C(COCH3) group, the group Z-B attaches to the W ring atom); when X is (a) or (b), Z = bond, O, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO or NHCONHCH2, but when X is -N(R5)-CH2-group, Z represents a CH2CH2 or CH2O group or Z and B together represent a 2,3-dihydro-benzo[l,4]dioxin-2-yl group; and B is a monocyclic or bicyclic aryl group or a monocyclic or bicyclic heterocycle, each of which is optionally substituted.

Double polysilicon EEPROM cell and corresponding manufacturing process

A two-level polysilicon EEPROM memory cell, of a type which comprises a floating gate (12) transistor connected serially to a selection transistor (14) and having a further control gate (15) overlying the floating gate (12) with an intermediate dielectric layer (11) therebetween. A region (10) including a double implant (18,19) of the same dopant at two different concentrations is provided between the respective gate terminals of the selection transistor (14) and the memory cell (1).

Erythromycin derivatives endowed with antiinflammatory activity

Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification; provided, however, that R1 is not a dimethylamino group when R3 is hydroxy, and both R2 and R4 are a hydrogen atom; R1 is not a dimethylamino group when in the substituent =N-O-R5 in 9-position, R5 is a hydrogen atom, a linear or branched C1-C5 alkyl, an unsubstituted benzyl group, or a chain -(CH2)rX-(CH2)m-Y-(CH2)n-A where r is 1, X is O, m is 2, Y is O, n is 1, and A is H; and R1 is not a methylethylamino group when in the substituent =N-O-R5 in 9-position, R5 is a linear or branched C1-C5 alkyl or an unsubstituted benzyl group. Compounds of formula (II) are also disclosed, wherein the substituents are as defined in the specification; provided, however, that R1 is not an N,N-dimethyl amino group, or R1 is not an N,N-dimethyl amino-N-oxide group when R is a hydrogen atom. The compounds of formula (II) are useful intermediates in the preparation of compounds of formula (I). The compounds of formula (I) are useful in the treatment of inflammatory or respiratory diseases.

High voltage field effect transistor and method for its production

Method of making asymmetric nonvolatile memory cell

A nonvolatile memory having a cell comprising an N + type source region and drain region embedded in a P - type substrate and surrounded by respective P-pockets. The drain and source P-pockets are formed in two different high-angle boron implantation steps designed to optimize implantation energy and dosage for ensuring scalability of the cell and avoiding impairment of the snap-back voltage. The resulting cell also presents a higher breakdown voltage as compared with known cells.

A method for manufacturing MOSFET transistors by means of inclined implants

Novel heterocyclic compounds as mglu5 antagonists

In Compounds I: Z is a group of the formula, m is 0, 1 or 2; n is 0, 1 or 2; Y is a linking group or is absent; R' is H or OH or is absent; ---- is an optional double bond; and R1, R2 and R3 are selected from a wide range of optionally substituted alkyl, cycloalkyl, aryl and heterocyclic groups. Compounds I are mGlu5 antagonists useful for the treatment of neuromuscular dysfunction of the lower urinary tract, migraine and gastroesophagael reflux disease in mammals. Preferred Compounds I are those having the formula

METHOD FOR THE PRODUCTION OF ENANTIOMINE-PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES.

EEPROM cell with double polysilicon layer and its manufacturing process

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Circuit structure for memory matrix and corresponding manufacturing processes

2-(acylthio)methyl dihydropyridines, and pharmaceutical compositions containing them

Compounds of formula I wherein R 1 is an alkoxy carbonyl, aminocarbonyl, acetyl, benzyl, cyano or nitro group; R 2 is as optionally substituted phenyl, aryl, hetaryl residue; R 3 is an alkoxy-carbonyl group, X is an oxygen or sulphur atom, R 4 is hydrogen, an optionally substituted alkyl, cycloalkyl, alkenyl group, Y is a single bond oxygen, sulphur or substituted nitrogen atom. Compounds of formula I are prepared by acylation from a 2-mercaptomethyl-1,4-dihydropyridine and are useful in therapy.

Double polysilicon EEPROM cell and corresponding manufacturing process and programming method

A method for programming a two-level polysilicon EEPROM memory cell, which cell is implemented in MOS technology on a semiconductor substrate and comprises a floating gate transistor and a further control gate overlying the floating gate with a dielectric layer therebetween, provides for the application of a negative voltage to the control gate during the cell write phase. This enables the voltages being applied across the thin tunnel oxide layer to be distributed so as to reduce the maximum amount of energy of the "holes" and improve the oxide reliability. In addition, by controlling the rise speed of the impulse to the drain region during the write phase, and of the impulse to the control gate during the erase phase, the maximum current flowing through the tunnel oxide can be set and the electric field being applied to the tunnel oxide kept constant, thereby the device life span can be extended.

Process for preparation of enantiomerically pure polysubstituted 1,4-dihydropyridines

A process for the optical resolution of racemic 1,4-dihydropyridines, containing isothioureido groups. Salification of racemic isothioureas with optically active acids produces diasteroisomeric mixtures of isothiouronium salts, that, using conventional techniques, are separated in the individual components to give optically pure isothioureides of 1,4-dihydropyridines and salts thereof with conventional acids. Said optically pure 1,4-dihydropyridines can then be subjected to desulphuration and to different transformations to give other enantiomerically pure and therapeutically useful 1,4-dihydropyridines.

Tienopyrankarboksamidderivater

Macrolide compounds endowed with antiinflammatory activity

Macrolide compounds endowed with antiinflammatory activity are described, an d more particularly macrolide derivatives lacking cladinose in position 3, wit h antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient.

Phthalazine derivatives as phosphodiesterase 4 inhibitors

Compounds of formula I wherein R and R1 are as defined in the description.Th e compounds of formula I are PDE 4 inhibitors.

Method of manufacturing a circuit containing non-volatile memory cells and edge transistors, and corresponding IC

2- (ACYLTI) METHYL DIHYDROPYRIDINE, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

A PROCEDURE FOR THE PREPARATION OF ENANTIOMERALLY PURE POLY-SUBSTITUTED 1,4-DIHYDROPYRIDINES.

A process for the optical resolution of racemic 1,4-dihydropyridines, containing isothioureido groups. Salification of racemic isothioureas with optically active acids produces diasteroisomeric mixtures of isothiouronium salts, that, using conventional techniques, are separated in the individual components to give optically pure isothioureides of 1,4-dihydropyridines and salts thereof with conventional acids. Said optically pure 1,4-dihydropyridines can then be subjected to desulphuration and to different transformations to give other enantiomerically pure and therapeutically useful 1,4-dihydropyridines.

1- (n-phenylaminoalkyl) -piperazine derivatives substituted in position 2 of the phenolic ring

"DERIVADOS DE 1-(N-FENILAMINOALQUIL)-PIPERAZINA SUBSTITUìDA NA POSIçãO 2 DO ANEL FENìLICO". Derivados de 1-(N-fenilaminoalquil)-piperazina da fórmula: (R = H, alquil-CO, cicloalquil-CO, cicloalquil-CO substituído ou heteroaril-CO monocíclico; R~ 1~ = H ou alquila inferior; R~ 2~ = halogênio, alcóxi, fenóxi, NO~ 2~, CN, acila, NH~ o~, NH(acila), alquil-SO~ 2~NH, alcoxicarbonila, NH~ 2~CO, (alquil)NHCO, (alquil)~ 2~NCO, (acila)NHCO, CF~ 3~ ou polifluoroalcóxi; B = benzilo ou arila mono ou bicíclica ou heteroarila, todos opcionalmente substituídos que ligam-se aos receptores 5HT~ 1A~ e são úteis para tratamento de disfunções neuromusculares do trato urinário inferior. O uso destes compostos para preparação de um medicamento para este tratamento é reivindicado e alguns dos compostos (com valores de B restritos) são reivindicados propriamente.

Tienopyrankarboksamidderivater

PROCESS FOR INCREASING THE THERMAL CONVECTION SPEED IN A HEAT-MELT POLYMER

Ce procédé permet d'augmenter la vitesse de transmission de la chaleur par convection thermique dans un polymère thermofusible, notamment un polyéthylène téréphtalate, en exposant le polymère simultanément à une source de rayonnement thermique et à des vibrations ultrasoniques. Les vibrations ultrasoniques sont appliquées de préférence par intermittence sur une surface du polymère au moyen d'une sonotrode alimentée par un générateur d'ultrasons, soit directement, soit par l'intermédiaire d'un liquide en contact avec le polymère.

Disposable cigarette-end receptacle

Disposable cigarette-end receptacle (2) that comprises an inlet orifice (6) having a conical mouth (8) towards the outside. The inside diameter of this orifice (6) is calibrated so as to grip a first cigarette end when it is introduced, to hold it in place and to prevent its withdrawal, this cigarette end thus serving as a plug for the receptacle (2). This orifice (6) is connected to a receptacle (4), the only exit of which is the inlet orifice (6). This receptacle (4) extends substantially along the axis of the inlet orifice (6), the minimum length of this closed receptacle (4), along this axis, corresponding to that of a standard cigarette.

High-voltage transistor structure for handling high-voltages in CMOS integrated circuits

High-voltage transistor structure, particularly for handling programming and/or programming and erasing voltages for electrically programmable and/or electrically programmable and erasable non-volatile memory cells which are integrated together with the high-voltage transistor and a low-voltage logic circuitry in a same semiconductor chip, the logic circuitry comprising first conductivity type channel transistors and second conductivity type channel transistors respectively formed inside second conductivity type wells (2) and first conductivity type wells (3), the first and second conductivity type wells (2,3) formed in a common substrate (1) of the first conductivity type which forms a common substrate of the semiconductor chip, the high-voltage transistor comprising an insulated gate electrode (10) and source and drain electrodes (9) at the sides of the insulated gate electrode (10). The insulated gate electrode (10) is insulated from the underlying common substrate (1) of the first conductivity type by a portion of a thick field oxide (4), and the source and drain electrodes (9) are doped regions of a second conductivity type formed directly in said common substrate (1).

Thienopyranecarboxamide derivatives, process for the preparation thereof, pharmaceutical compositions containing them

SINGLE LEVEL EEPROM MEMORY CELL OF POLYSILICIO WITH TUNNEL OXIDE ZONE

spiroheterocyclic compounds as mglu5 antagonists and pharmaceutical composition containing said compounds

compostos espiro-ehetrocíclicos inéditos como antagonistas mglu5. a invenção diz respeito a compostos com a fórmula geral i em que x é o ou s; r1 é c,n,o ou s; r1a é ch, ch2, n ou nh: r2 é um ligação, ch ou ch2; é 1,2 ou 3; n é 1 ou 2; quando n é 2 ou m é 2ou 3, o anel contendo r1 pode ser fundido com um anel de benzeno; cada - representa uma ligação única ou dupla desde que uma ligação dupla se estenda do átomo de carbono no qual r3-c=c - é ligado e que nenhum átomo de carbono do anel carregue duas ligações duplas; e r3, r4 e r5 representem uma ampla faixa de substituintes. esses compostos são seletivos para o receptor metabotrópico de mglu5. eles, seus solvatos, gidratos, enantiômetros, diastereômeros, n-óxidos e sais farmceuticamente aceitáveis, e composições farmacêuticas contendo-os, podem ser usados para tratar doenças ou dist´rubios do trato urinário inferior, especialmente disfunções neuromusculares do trato urinário inferior. eles podem também ser usados pra o tratamento de enxaqueca; para o tratamento de doença de refluxo gastroesófagico (gerd); para o tratamento de distúrbio de ansiedade; para o tratamento de abuso, dependência de substância e distúrbio da retirada da substância; para o tratamento de distúrbio de dor neuropática; e para o tratamento de distúrbios da síndrome do x frágil. spiro-ehetrocyclic compounds unpublished as mglu5 antagonists. The invention relates to compounds of the general formula wherein x is o or s; R1 is c, n, o or s; r1a is ch, ch2, n or nh: r2 is a bond, ch or ch2; is 1,2 or 3; n is 1 or 2; when n is 2 or m is 2or 3, the ring containing r 1 may be fused to a benzene ring; each represents a single or double bond provided that a double bond extends from the carbon atom to which r3-c = c is bonded and no ring carbon atom carries two double bonds; and r3, r4 and r5 represent a wide range of substituents. These compounds are selective for the mglu5 metabotropic receptor. They, their solvates, hydrates, enantiometers, ...

PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE POLYSUBSTITUTED 1,4-DIHYDROPYRIDINES.

EEPROM MEMORY CELL WITH A SINGLE POLYSILIZER LAYER, BITWRITELY WRITABLE AND ERASABLE.

Heterobicyclic compounds, preparation processes thereof and pharmaceutic compositions which contain them thereof

Invenţia se referă la compuşi heterobiciclici cu formula generală I:(I)în care heteroatomul X este, preferabil, oxigen, gruparea W este, preferabil, o grupare carbonil, heterociclul preferat este un ciclu 4-oxo-4h-1-benzopiranic, cu un număr variat de substituenţi, Y include -COO, -CONH-, -O-, SONH, Z este un lanţ alchilenic şi B este o amină complexată; invenţia se referă şi la procedee pentru prepararea acestor compuşi şi compoziţii farmaceutice care care îi conţin. Aceşti compuşi, precum şi promedicamentele lor, enantiomerii, diastereoizomerii, N-oxizii şi sărurile lor, acceptabile farmaceutic, sunt utili pentru tratamentul hipertensiunii şi al tulburărilor tractului urinar, asociate cu hipertrofia prostatică benignă şi pentru tratamentul altor boli. The invention relates to heterobicyclic compounds of the general formula I: (I) wherein the heteroatom X is preferably oxygen, the W group is preferably a carbonyl group, the preferred heterocycle is a 4-oxo-4H-1-benzopyranic ring, a variety of substituents, Y includes -COO, -CONH-, -O-, SONH, Z is an alkylene chain and B is a complexed amine; the invention also relates to processes for the preparation of these compounds and pharmaceutical compositions containing them. These compounds, as well as their pharmaceutically acceptable prodrugs, enantiomers, diastereoisomers, N-oxides and salts, are useful for the treatment of hypertension and urinary tract disorders associated with benign prostatic hypertrophy and for the treatment of other diseases.

Packaging for liquid or powdered products

The packaging of the invention consists in an assembly composed of a cardboard box and of a bottle made from plastic material contained in this box. It is equipped with flexible shoulders enabling the spout to be retracted inside the box or brought outside the latter, the neck of the bottle then being engaged in an opening provided in the cover of the box.

Method for producing electrically erasable and programmable read-only memory cells with a single polysilicon level

A method for producing electrically erasable and programmable read-only memory cells with a single polysilicon level, including the use of a sacrificial layer (5) of silicon oxide to produce a high-thickness silicon oxide layer on the active area. The active area of the cell is protected from heavy source and drain implantation in order to improve reliability.

Phosphonopyridines and their 1,4-dihydroderivatives

5-Phosphono-1,4-dihydropyridines and pyridines of formula I <CHEM> wherein m is zero or 1, R1 and R2 may be hydrogen, alkyl or aryl groups, R3 is an optionally substituted aryl or hetaryl group, R4 is a carboxyester, cyano, nitro, acetyl, benzyl or carboxyamido group, R5 and R are alkyl chains optionally substituted or interrupted by heteroatoms, double or triple bonds, are endowed with a calcium antagonistic effect.

Thienopyranecarboxamide derivatives

Compounds (I) (R = aryl, cycloalkyl or polyhaloalkyl, R1 = alkyl, alkoxy, polyfluoroalkoxy, hydroxy or trifluoromethanesulphonyloxy, each of R2 and R3 independently = H, halogen, alkoxy or polyfluoroalkoxy, n is 0, 1 or 2) and their N-oxides or pharmaceutically acceptable salts are endowed with enhanced selectivity for the alpha 1 adrenergic receptor and a low activity in lowering blood pressure. This activity profile makes these compounds useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), in lowering intraocular pressure, in the treatment of cardiac arrhythmia and erectile and sexual dysfunction, and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). Compounds (I) <i>per se</i>, pharmaceutical compositions containing compounds (I) and medical uses of compounds (I) are claimed.

Flavone derivatives.

Package for liquid or dusty products

Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors

Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR5.

Secure offline transaction system using digital tokens and a secure ledger database

A payer transaction device enables secure offline transactions using a secure element providing a payer account database, a ledger database, and a wallet application. While the payer transaction device is not connected to the Internet, the wallet application receives a payee identifier and a transaction amount and verifies the amount is less than an available payer account balance in the payer account database. In response, the wallet application creates a digital token that allocates the amount from the payer account balance to the payee identifier and records the digital token in a payer ledger in the ledger database, which reduces the available payer account balance by the amount. The wallet application then transfers the digital token to a payee transaction device over a peer-to-peer wireless connection and, subsequently, the digital token is synchronized with a ledger tracking system through the Internet.

2-Methylthiomethyl-dihydropyridines, process for their preparation and pharmaceutical compositions containing them.

Compounds of formula I <CHEM> wherein R1 is a cyano, nitro, benzoyl, acetyl, amido or alkoxycarbonyl group; - R2 is a substituted aryl- or heterocyclic residue; - R3 is an alkoxycarbonyl group; - R4 and R5, being the same or different, are hydrogen, alkyl, aryl or heterocyclic groups; - Y is oxygen, sulphur or substituted or unsubstituted nitrogen atom, that can be a part of a heterocyclic ring; n is 0, 1 or 2 - R6 and R10, that can be the same or different, are: hydrogen; C1-C6-alkyl optionally substituted by hydroxy, amino, monoalkyl and dialkylamino, C1-C6 -alkoxy, C1-C6-alkoxycarbonyl, C1-C3-carbonyloxy, aryl, heteroaryl and cycloalkyl; a C1-C12-alkanoyl, aroyl or heteroaryl group optionally substituted by halogen, nitro, amino monoalkylamino, dialkylamino, hydroxy, C1-C6- alkoxy, C1-C6-alkoxycarbonyl, C1-C6-alkylthio, C1-C3-carbonyloxy, aryl, heteroaryl, cycloalkyl groups. These compounds are useful in therapy as cardiovascular agents.

Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors

Heterobicyclic compounds

User interface for establishing mappings from internal metadata to external metadata

A solution is provided that allows a user to provide an alternate set of metadata for any number of data points within a report, while in a report design environment. They may lay down a grid on the work area and specify the data by placing the relevant dimensional metadata, extracted from the source, in the grid as row headings and column headings. The user may then select either a column or a row from the grid and upon doing so may be provided with a mechanism to define alternate metadata that can describe all data points that are in the column or row in the target system. This allows for a much more user-friendly environment in which to specify metadata mappings between internal sources and external sources.

Thienopyranecarboxamide derivatives

Compounds (I) (R = aryl, cycloalkyl or polyhaloalkyl, R1 = alkyl, alkoxy, polyfluoroalkoxy, hydroxy or trifluoromethanesulphonyloxy, each of R2 and R3 independently = H, halogen, alkoxy or polyfluoroalkoxy, n is 0, 1 or 2) and their N-oxides or pharmaceutically acceptable salts are endowed with enhanced selectivity for the .alpha.1 adrenergic receptor and a low activity in lowering blood pressure. This activity profile makes these compounds useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), in lowering intraocular pressure, in the treatment of cardiac arrhythmia and erectile and sexual dysfunction, and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). Compounds (I) <i>per se</i>, pharmaceutical compositions containing compounds (I) and medical uses of compounds (I) are claimed.

Circuit structure for memory matrix and corresponding manufacturing processes

EEPROM memory cell with two levels of polysilicon and a tunnel oxide zone

The cell comprises a selection transistor (51), a pickup transistor (52), a thin oxide zone (56), a floating gate (58) superimposed on said thin oxide zone (56) and made with a first layer of polysilicon (57) in a single piece with a first gate (59) of the pickup transistor (52), and a control gate (61) superimposed on said first gate (59) of the pickup transistor (52) and made with a second polysilicon layer (61). The latter also forms the selection transistor gate (51) in a single piece.

Packaging for liquid or pulverulent products

ABSTRACT The packaging of the invention consists in an assembly composed of a cardboard box and of a bottle made from plastic material contained in this box. It is equipped with flexible shoulders enabling the spout to be retracted inside the box or brought outside the latter, the neck of the bottle then being engaged in an opening provided in the cover of the box.

EEPROM STORAGE CELL WITH A POLYSILIZE LAYER AND A TUNNEL OXIDE ZONE.

1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring

1-(N-phenylaminoalkyl)-piperazine derivatives of formula (I), (R = H, alkyl-CO, cycloalkyl-CO, substituted cycloalkyl-CO or monocyclic heteroaryl-CO; R1 = H or lower alkyl; R2 = halogen, alkoxy, phenoxy, NO2, CN, acyl, NH2, NH(acyl), alkyl-SO2NH, alkoxycarbonyl, NH2CO, (alkyl)NHCO, (alkyl)2NCO, (acyl)NHCO, CF3 or polyfluoroalkoxy; B = benzyl or mono- or bicyclic aryl or heteroaryl, all optionally substituted) bind to 5HT1A receptors and are useful for the treatment of neuromuscular dysfunctions of the lower urinary tract. The use of these compounds for the preparation of a medicament for this treatment is claimed, and some of the compounds (with restricted B values) are claimed per se.

Manufacture of insulated gate field effect transistor

(57)【要約】 【課題】 均一で一定長のチャネルを害することなく注 入工程数を減少させる。 【解決手段】 本発明の方法は、基板上に能動領域（８ １）の境界を定める工程と、この能動領域上に基板から 絶縁されたゲート電極（８２，８３，８８）を形成する 工程と、ゲート電極をマスクとして用い、ドーピング用 のイオンビームを用いる数回の注入工程を基板の上面に 行なってソース及びドレイン領域を形成する工程とを有 する。注入ビームの方向は基板の上面に対するイオンビ ームの傾斜角と、基板上の基準線（８０）に対する向き （４５°，１３５°，２２５°，３１５°）とによって 規定する。ゲート電極細条（８２，８３，８８）の幅 は、その設計段階で、基準線（８０）に対する細条の向 きと、注入イオンビームの方向とに応じて決定する。

N,n-disubstituted diazocycloalkanes useful for the treatment of cns disorders due to serotonergic dysfunction

N,N-Disubstituted diazocycloalkanes of the formula (I): (R 1 = halogen, R 2 = (C 3 -C 8 )-cycloalkyl, R 3 = (C 1 -C 4 )-alkoxy or (C 1 -C 4 )-haloalkoxy group, m is 1 or 2, n is 1 or 2) have affinity for serotoninergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptor. 1,4-Disubstituted-piperazines (n = 1) are preferred. R 1 is preferably F in the 2-position, R 2 is preferably cyclohexyl, and R 3 is preferably a methoxy or 2,2,2-trifluoroethyl group. Preferably, m = 1.

Phenylalkylamines and pyridylalkylamines

Compounds of formula (I): (A is CH or N, R and R 1 are a wide range of substituents, Q is CO, CHOH or CHOR 2 , R 2 is alkyl, alkenyl, alkynyl or cycloalkyl group, each of which is optionally substituted, or is alkanoyl, alkanoyoxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminothiocarbonyl, alkylaminothiocarbonyl or dialkylaminothiocarbonyl, R 3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclic group, each of which is optionally substituted, m is 1 or 2, R 4 is an aryl or heteroaryl group, either of which is optionally substituted, R 5 is either (II) or (III), wherein m is 1 or 2, R 6 is H or alkyl, R 7 is O, S, NR 6 or CH 2 , B is a bond, O, S, NR 6 or CH 2 and -------- represents a single or double bond) have affinity for serotoninergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptor activity.

Novel spiroheterocyclic compounds as mglu5 antagonists

The invention provides compounds having the general formula (I) wherein X is O or S; R1 is C, N, O or S; R1a is CH, CH2, N or NH; R2 is a bond, CH or CH2; m is 1, 2 or 3; n is 1 or 2; when n is 2 or m is 2 or 3, the ring containing R1 may be fused with a benzene ring; each --- represents a single or double bond provided that one double bond extends from the carbon atom to which R3-C=C- is bonded and that no ring carbon atom bears two double bonds; and R3, R4 and R5 represent a wide range of substituents. These compounds are selective for the metabotropic mGlu5 receptor. They, their solvates, hydrates, enantiomers, diastereomers, N-oxides and pharmaceutically acceptable salts, and pharmaceutical compositions containing them, can be used to treat diseases or disorders of the lower urinary tract, especially neuromuscular dysfunctions of the lower urinary tract. They may also be useful for the treatment of migraine; for the treatment of gastroesophageal reflux disease (GERD); for the treatment of anxiety disorder; for the treatment of abuse, substance dependence and substance withdrawal disorder; for the treatment of neuropathic pain disorder; and for the treatment of fragile X syndrome disorders.

Package for liquid or powdered products

The packaging of the invention consists in an assembly composed of a cardboard box and of a bottle made from plastic material contained in this box. It is equipped with flexible shoulders enabling the spout to be retracted inside the box or brought outside the latter, the neck of the bottle then being engaged in an opening provided in the cover of the box.

Ετεροκυκλικες ενωσεις για χρηση στην αγωγη διαταραχων της ουροποιητικης οδου

Οι ενώσεις τύπου (I) είναι χρήσιμες για την αγωγή διαταραχών της ουροποιητικής οδού. Στις ενώσεις I, R1 = ένας ή περισσότεροι υποκαταστάτες επιλεγόμενοι από Η, αλογόνο, ΟΗ, αλκύλιο, αλογονοαλκύλιο, αλκοξύλιο, αλογονοαλκοξύλιο, ΝΟ2, νιτροομάδα, φαινύλιο, υποκατασταθέν φαινύλιο, ετεροκυκλικό δακτύλιο, υποκατασταθέντα ετεροκυκλικό δακτύλιο, NR3R4 (τα R3 και R4 είναι Η, αλκύλιο, ακύλιο ή αλκοξυκαρβονύλιο).·R2 = ένας ή δύο υποκαταστάτες επιλεγόμενοι από Η, αλκύλιο· Υ = CH2 ή ένας δεσμός· Q = CO, CS ή SΟ2-Α = αλκύλιο, αλκενύλιο, κυκλοαλκύλιο, κυκλοαλκενύλιο, αρύλιο, ετεροκυκλικός δακτύλιος, αλκυλαμίνη, διαλκυλαμίνη, αρυλαμίνη ή αρυλαλκυλαμίνη, εκάστη των οποίων φέρει προαιρετικά υποκατάσταση· το n είναι 1 ή 2· Χ = μία αμινούχος μονάδα επιλεγόμενη από τους τύπους (a), (b) και -N(R5)-CH2- (R5 = Η, ομάδα μεθυλίου, βενζυλίου· W = δεσμός, Ν, CH, CH2, C(CN)C(OH) ή C(COCH3) (όταν το W παριστά ένα άτομο αζώτου ή μία ομάδα CH, C(CN)C(OH) ή C(COCH3), η ομάδα Ζ-Β συνδέεται με το άτομο δακτυλίου W). όταν το Χ είναι (a) ή (b), Ζ = δεσμός, Ο, S, CH2, CH2CH2, CO, CHOH, OCH2, NH, NHCO ή NHCONHCH2, αλλά όταν το Χ είναι ομάδα -N(R5)-CH2-, το Ζ παριστά μία ομάδα CH2CH2 ή CH2Ο ή τα Ζ και Β ομού παριστούν μία ομάδα 2,3-διυδρο-βενζο[1,4]διοξιν-2-υλίου· και το Β είναι μία ομάδα μονοκυκλικού ή δικυκλικού αρυλίου ή μονοκυκλικού ή δικυκλικού ετερο-κυκλικού δακτυλίου, εκάστη των οποίων μπορεί να φέρει υποκατάσταση.

Derivados de piperazina activos no trato urinario inferior

Flacone in plastica per prodotti diversi.

Makrolidverbindungen mit antiinflammatorischer wirkung

Phthalazinderivate als phosphodiesterase-4-hemmer

Processo per la preparazione di 1,4 diidropiridine polisostituite in forma enantiomericamente pura.

Dispositivo médico extraglótico para intubación orotraqueal a ciegas

La presente invención está relacionada con un dispositivo médico extraglótico para intubación orotraqueal a ciegas que comprende un orificio de inserción del tubo, un elevador de epiglotis, un cuerpo seleccionado de un cuerpo con forma de media caña y un cuerpo tubular corto, una cazoleta que no requiere inflado y un orificio de salida a la vía aérea. El campo de aplicación de la presente invención está dirigido al sector de la medicina, específicamente en lo relacionado con el establecimiento de vía aérea a ciegas, sin necesidad de movilizar la columna cervical, de fácil uso, con una adecuada tasa de éxito y una curva de aprendizaje baja.

Derivati benzopiranici e benzotiopiranici

2 metiltiometildiidropiridine, un processo per laloro preparazione e composizioni farmaceutiche che le contengono.

Electronic transaction fobs

Systems and methods for electronic fobs that communicate via short range communications protocols to conduct transactions with a nearby device are provided. Such electronic fobs may use electronic tokens to conduct electronic transactions, such as payment transactions. Account data may be stored within a secure element of the electronic fob. Electronic tokens may also be stored by the secure element. Using such data and/or tokens, electronic fob may write electronic tokens to be used in electronic transactions. Also, such electronic fobs may also be used to perform other tasks and interface with other devices.

Physical stand for multiple device orientations and peripheral card reader

There are provided systems and methods for a physical stand for multiple device orientations and peripheral card reader. A device stand may include a dock that allows for placement and securing of a computing device within the device case, such as through a locking or connecting mechanism. The device dock further includes a peripheral component, such as a physical card reader, that allows for reading and entry of card data into the computing device for use with an electronic transaction processing application on the computing device. This allows the computing device to process transactions electronic with an online service provider. Further, the device stand includes a hinge or joint that allows for rotating and inverting of the computing device over a curved extension from a base of the device stand, which allows the computing device to be viewed in multiple directions and orientations.

Wearable payment device

A wearable device receives authentication information from a user. In response to verifying the authentication information, the wearable device provides the user with access to one or more payment capabilities of the wearable device. In response to determining that the wearable device has been switched into an open state, the wearable device removes access to the one or more payment capabilities of the wearable device.